10.66
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Trillium Therapeutics Inc | TRIL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 10.66 | 04:33:39 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 10.66 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 10.52 | 11.67 | 1.15 | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 10.66 | USD |
Trillium Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 945.38M | 88.68M | 12.35M | $ 126.57k | $ - | -2.26 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Trillium Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TRIL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 12.22 | 12.48 | 10.56 | 11.27 | 1,736,900 | -1.56 | -12.77% |
| 1 Month | 12.70 | 14.93 | 10.56 | 12.50 | 1,455,545 | -2.04 | -16.06% |
| 3 Months | 11.80 | 15.9226 | 10.56 | 12.89 | 1,722,400 | -1.14 | -9.66% |
| 6 Months | 10.19 | 20.96 | 8.54 | 13.98 | 2,141,565 | 0.47 | 4.61% |
| 1 Year | 6.35 | 20.96 | 2.50 | 10.28 | 1,990,496 | 4.31 | 67.87% |
| 3 Years | 7.20 | 20.96 | 0.2405 | 6.61 | 1,256,435 | 3.46 | 48.06% |
| 5 Years | 7.25 | 20.96 | 0.2405 | 6.70 | 796,416 | 3.41 | 47.03% |
Trillium Therapeutics Description
| Trillium Therapeutics Inc is a Canadian clinical stage immuno-oncology company which is engaged in developing therapies for the treatment of cancer. The lead program of the company is TTI-621 which is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. The company has proprietary medicinal chemistry platform, using fluorine chemistry which permits the creation of new chemical entities with pharmacological properties. The company operates through the single segment being Research and development of therapies for the treatment of cancer. |
